{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058981","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.749050+00:00","generated_at":"2026-06-02T00:45:26.652445+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CV Sciences acquires Elevated Softgels for up to $1M; plans in-sourcing of +PlusCBD production","bullets":["Total consideration up to $1,000,000: $100k cash, 17.4M shares ($700k), plus earnout up to $200k.","Elevated Softgels is a GMP-certified, FDA-registered manufacturer of softgels and tinctures.","CEO says acquisition expected to be accretive in first year; softgels and tinctures were ~50% of 2023 sales.","Plans to in-source manufacturing of +PlusCBD branded products for meaningful cost savings.","Earnout thresholds: $200k if net revenue ≥$700k in 12 months, $0 if <$550k, with intermediate steps."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058981","json":"https://secwatch.observer/filing/0000950170-24-058981.json","markdown":"https://secwatch.observer/filing/0000950170-24-058981.md","text":"https://secwatch.observer/filing/0000950170-24-058981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024058981/0000950170-24-058981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024058981/cvsi-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:45:26.652445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa28229be308748b72271f214ceb9d33a060871b","claim":"CV Sciences, Inc. entered into Membership Interest Purchase Agreement with Elevated Softgels, LLC, Clayton J. Montgomery, Chris Fagan, Andrew Kester, Timothy McGreer valued at Cash payment of $100,000; issuance of 15,854,185 restricted shares valued at $637,000; issuance of 1 (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024, CV Sciences, Inc. (the “Company”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) by and among the Company, Elevated Softgels, LLC, a Delaware limited liability company (“Elevated Softgels”), Clayton J. Montgomery (a “Member”), Chris Fagan, Andrew Kester, and Timothy McGreer, pursuant to which the Company purchased all of the outstanding equity interests in Elevated Softgels, resulting in Elevated Softgels becoming a wholly owned subsidiary of the Company (the “Acquisition”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024058981/0000950170-24-058981-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Elevated Softgels, LLC, Clayton J. Montgomery, Chris Fagan, Andrew Kester, Timothy McGreer"},{"label":"Value","value":"Cash payment of $100,000; issuance of 15,854,185 restricted shares valued at $637,000; issuance of 1"},{"label":"Effective","value":"2024-05-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}